Vensana Capital announced the closing of Vensana Capital III with $425 million in committed capital. This fund was oversubscribed at its hard cap with the support of the firm’s existing limited partners alongside select new institutional investors, and it brings Vensana’s total capital under management to about $1 billion.
Launched in 2019, Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with innovative medical technology companies in their development and commercial stages. And the firm invests across all areas of medical technology, with a particular focus on medical device and data science-oriented companies that have the potential to create new clinical standards of care while also helping to make healthcare more efficient, accessible, and cost-effective.
Since its founding, Vensana has been one the most active medtech investors, with a diversified portfolio of companies advancing first-in-class and best-in-class products. And the firm has partnered with over 20 companies to date and has seen six exits totaling nearly $3 billion in value, including the acquisitions of Artelon, Intact Vascular, Personal Genome Diagnostics, Relievant Medsystems, and Vesper Medical, as well as the initial public offering of CVRx.
Vensana’s founders and Managing Partners Kirk Nielsen and Justin Klein, MD, JD, are joined by a team of experienced investors, including Partners Amrinder Singh, Cynthia Yee, Greg Banker, and Mike Kramer, Venture Partner Bill Hoffman, Investment Professionals Allison King and Petra Gorombei, PhD, and Partner & Chief Financial Officer Steve Schwen. And Vensana’s investment team is further strengthened by an advisory board comprised of medical technology entrepreneurs, senior executives, and subject matter experts.
KEY QUOTES:
“We are incredibly proud of the progress Vensana has made since launch as we work tirelessly to build the leading medtech investment and company building platform, and we are beyond grateful for the continued strong support of our limited partners.”
– Vensana Managing Partner Kirk Nielsen
“Our entire team is excited about the opportunity ahead as we continue to partner with entrepreneurs who are transforming healthcare with breakthrough innovations in medical technology. We approach each day mindful of the impact that our work has on the missions of our limited partners, on our portfolio companies and their teams, and – most importantly – on our clinician partners and their patients.”
– Managing Partner Justin Klein
